Welcome to our dedicated page for Endo International plc news (Ticker: ENDP), a resource for investors and traders seeking the latest updates and insights on Endo International plc stock.
Endo International plc (OTC: ENDPQ) is a leading specialty pharmaceutical company dedicated to improving the lives of patients through innovative and high-quality therapies. With a global team of passionate professionals, Endo transforms insights into effective treatments and ensures these are available to those who need them most.
Endo's core business revolves around the development, manufacturing, and marketing of branded and generic pharmaceutical products. The company focuses on areas such as pain management, urology, endocrinology, and oncology, catering to various unmet medical needs. Over the years, Endo has built a robust portfolio of products that enhance the quality of life for patients worldwide.
Recent Achievements and Projects:
- On September 21, 2023, Endo announced the presentation of data from clinical studies of collagenase clostridium histolyticum (CCH) for treating plantar fibromatosis at the American Orthopaedic Foot & Ankle Society's annual meeting. These studies showed improvement in nodule hardness and patient satisfaction, with a consistent safety profile.
- Endo has completed a Phase 2 study of CCH and anticipates beginning the pivotal Phase 3 program later this year. This effort underscores Endo's commitment to developing nonsurgical treatment options for conditions like plantar fibromatosis.
Endo's financial condition is currently under strategic restructuring, including Chapter 11 proceedings, aimed at addressing the company's liabilities and ensuring long-term viability. Despite these challenges, Endo continues to prioritize its mission of delivering life-enhancing therapies.
Endo's partnerships and collaborations play a crucial role in its success. By working with healthcare professionals, research institutions, and other industry stakeholders, Endo stays at the forefront of pharmaceutical innovation and effectively meets market demands.
For more information about Endo and its latest news, visit www.endo.com or connect with the company on LinkedIn.
Endo International plc (NASDAQ: ENDP) reported a 4% increase in total revenues to $789 million for Q4 2021, but faced a significant loss from continuing operations of $557 million. Adjusted net income per share from continuing operations rose 12% to $0.84. The Branded Pharmaceuticals segment grew by 2%, mainly driven by a 14% increase in XIAFLEX® revenues. Looking ahead, Endo provided limited guidance for Q1 2022, citing uncertainties from VASOSTRICT® generic competition and ongoing COVID-19 impacts on specialty products.
Endo International plc (NASDAQ: ENDP) anticipates a Tennessee court will grant a default judgment against its subsidiaries, Endo Health Solutions and Endo Pharmaceuticals, in the case of Dunaway, et al. v. Purdue Pharma, L.P. This judgment is based on alleged discovery issues from another case. The court plans to begin a damages trial in April 2023. Endo disputes the ruling, claiming no basis for the sanctions and emphasizing that the plaintiffs had not sought discovery. This case involves claims from multiple Tennessee counties and cities regarding the sale of opioid medications.
Endo International plc has launched VASOSTRICT®, the first FDA-approved ready-to-use vasopressin injection in 100 mL pre-mix bottles. This product eliminates the need for preparation, potentially reducing waste and preparation errors, thereby enhancing patient care. VASOSTRICT® offers a two-year shelf life, with up to 12 months at room temperature, which can improve inventory management for healthcare providers. The product aims to streamline operations in hospitals and comply with safety standards.
Endo International plc (NASDAQ: ENDP) will announce its fourth-quarter and full-year 2021 financial results on February 28, 2022. A conference call and webcast will be held on March 1, 2022 at 7:30 am ET. The dial-in numbers are U.S./Canada (866) 497-0462 and International (678) 509-7598, with a passcode of 4272796. A replay will be available from March 1, 2022 to March 8, 2022. Access details for the call and replay can be found on the Endo investor website.
Endo International plc (NASDAQ: ENDP) announced a settlement to resolve all government-related opioid claims in Florida, involving a payment of up to $65 million. The settlement does not imply any admission of wrongdoing by Endo or its subsidiaries and is linked to claims set for trial in April 2022. While this settlement addresses some claims, Endo continues to litigate other opioid-related claims and explore strategic alternatives for a global resolution. The outcome of ongoing litigation remains uncertain and could impact future financial performance.
Endo International plc (NASDAQ: ENDP) announced new findings regarding its testosterone replacement therapy product, AVEED®, published in The Journal of Clinical Pharmacology. A pharmacokinetic modeling study suggests that a more frequent dosing schedule (every 8 weeks instead of 10) could reduce testosterone fluctuations and optimize serum testosterone levels for hypogonadal males. The current regimen involves a 3 mL (750 mg) injection every 10 weeks, but the new data indicates that 76.1% of patients might maintain normal testosterone levels with the 8-week regimen. Clinical validation is necessary.
Endo International plc (NASDAQ: ENDP) has appointed Dr. James P. Tursi as the new Executive Vice President of Global Research & Development, effective January 18, 2022. Dr. Tursi brings nearly 20 years of pharmaceutical experience, previously serving at Ferring Pharmaceuticals and other notable companies. His expertise spans various therapeutic areas, which will be crucial for Endo's goal of enhancing its product portfolio. This appointment is part of Endo's broader strategy to improve and expand its offerings, ultimately aiming to support the well-being of those they serve.
Endo International plc (NASDAQ: ENDP) has launched a new television commercial and awareness campaign, Watching Education Unfold, aimed at educating the public about Dupuytren's contracture, a condition affecting approximately 14 million Americans. The campaign utilizes real patient experiences to correct misinformation and encourage individuals to consult hand specialists. It features commercials on major TV networks and online platforms, as well as educational materials in doctors' offices. The initiative follows a previous campaign that included football legend John Elway, now focusing on everyday individuals.
Endo International plc (NASDAQ: ENDP) announced that Par Pharmaceutical has started shipping the first generic version of Merz's CUVPOSA® (glycopyrrolate) 1 mg/5 mL oral solution in the U.S. after receiving FDA approval for its Abbreviated New Drug Application. CUVPOSA® sales were approximately $27 million for the year ending October 31, 2021. Jon Holden, Endo's Senior VP, emphasized the importance of providing families with a generic option, enhancing the company's portfolio of cost-effective treatments.
Endo International plc (NASDAQ: ENDP) will present at the J.P. Morgan Healthcare Conference on January 11, 2022, at 8:15 a.m. EST. A live webcast of the event will be available on their website. Attendees are advised to connect about 10 minutes early to prepare for streaming.
Endo is a specialty pharmaceutical company that focuses on delivering quality therapies to enhance lives. They emphasize collaboration and innovation to provide effective treatments when needed. For more information, visit www.endo.com.
FAQ
What does Endo International plc do?
What recent achievements has Endo announced?
What are Endo's core therapeutic areas?
What is plantar fibromatosis?
What is Endo’s financial situation?
How is Endo addressing unmet medical needs?
Where can I find more information about Endo?
What is CCH and what is its significance?
Is CCH approved for treating plantar fibromatosis?
What partnerships does Endo engage in?
